[Antitumor activity of doxorubicin in respect to solid tumors in mice]

Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology
|November 1, 1986
PubMed

Insights

Doxorubicin exhibits significant antitumor effects against specific mouse cancers, showing high efficacy against lymphosarcoma and sarcoma 180. It also demonstrated selective activity against pregastric cancer and melanoma B-16.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Doxorubicin is an antibiotic developed in the USSR.
  • Antitumor antibiotics like rubomycin and carminomycin are established treatments.

Purpose of the Study:

  • To evaluate the antitumor activity of doxorubicin against four distinct solid mouse tumors.
  • To compare doxorubicin's efficacy with existing agents, rubomycin and carminomycin.

Main Methods:

  • In vivo study using mouse models.
  • Assessment of tumor growth inhibition and animal survival rates.
  • Testing against lymphosarcoma LIO-1, sarcoma 180, pregastric cancer OZh5, and melanoma B-16.

Main Results:

  • Doxorubicin demonstrated high antitumor activity against lymphosarcoma LIO-1 and sarcoma 180.
  • It showed superior selective antitumor activity against pregastric cancer OZh5 compared to rubomycin and carminomycin.
  • Doxorubicin was more effective in inhibiting melanoma B-16 growth, whereas carminomycin prolonged animal lifespan.

Conclusions:

  • Doxorubicin possesses significant antitumor properties against various mouse solid tumors.
  • Its efficacy varies across tumor types, with notable activity against specific cancers.
  • Doxorubicin presents a potentially valuable therapeutic option, with distinct advantages in certain cancer models.